Literature DB >> 16492715

Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.

Q Zhou1, M Hennenberg, J Trebicka, K Jochem, L Leifeld, E Biecker, T Sauerbruch, J Heller.   

Abstract

BACKGROUND AND AIMS: Portal hypertension in cirrhosis is mediated in part by increased intrahepatic resistance, reflecting an increased sensitivity of the hepatic microvasculature to vasoconstrictors. Activation of the RhoA/Rho-kinase pathway is essential for contraction of vascular smooth muscle. The aim of this study was to investigate RhoA/Rho-kinase mediated regulation of the intrahepatic vascular tone in cirrhotic rats.
METHODS: Cirrhosis was induced by bile duct ligation (BDL). Hepatic RhoA and Rho-kinase expressions were studied by real time reverse transcription polymerase chain reaction and western blot analysis. Hepatic Rho-kinase activity in rat and human livers was assessed as phosphorylation of the Rho-kinase substrate moesin. The effect of the Rho-kinase inhibitor Y-27632 on hepatic perfusion pressure was measured in livers perfused at constant flow. The in vivo effect of intravenous application of Y-27632 was studied by haemodynamic measurements.
RESULTS: Hepatic expressions of RhoA and Rho-kinase were increased at mRNA and protein level in BDL rats. Intrahepatic moesin phosphorylation was increased in livers from cirrhotic rats and patients with alcohol induced cirrhosis. Y-27632 reduced the basal perfusion pressure of in situ perfused livers in BDL rats but not in sham operated rats. Y-27632 reduced the sensitivity to methoxamine in isolated perfused livers in sham operated rats more than in BDL rats. In vivo, Y-27632 reduced portal pressure to a greater extent in BDL rats than in sham operated rats. Intrahepatic vascular resistance was decreased in response to bolus injection of Y-27632 in BDL rats but not in sham operated rats.
CONCLUSIONS: Upregulation of RhoA and Rho-kinase contributes to increased intrahepatic resistance in cirrhotic rats and to an increased sensitivity of cirrhotic livers to vasoconstrictors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492715      PMCID: PMC1860046          DOI: 10.1136/gut.2005.081059

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  53 in total

1.  Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids.

Authors:  V Shah; F G Haddad; G Garcia-Cardena; J A Frangos; A Mennone; R J Groszmann; W C Sessa
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 2.  The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide.

Authors:  D Rockey
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

3.  Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats.

Authors:  A J Elliot; L T Vo; V L Grossman; P S Bhathal; H J Grossman
Journal:  J Gastroenterol Hepatol       Date:  1997-04       Impact factor: 4.029

4.  Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat.

Authors:  V Shah; M Toruner; F Haddad; G Cadelina; A Papapetropoulos; K Choo; W C Sessa; R J Groszmann
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

5.  Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension.

Authors:  D C Rockey; J J Chung
Journal:  Gastroenterology       Date:  1998-02       Impact factor: 22.682

6.  RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts.

Authors:  R J Shaw; M Henry; F Solomon; T Jacks
Journal:  Mol Biol Cell       Date:  1998-02       Impact factor: 4.138

7.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.

Authors:  M Uehata; T Ishizaki; H Satoh; T Ono; T Kawahara; T Morishita; H Tamakawa; K Yamagami; J Inui; M Maekawa; S Narumiya
Journal:  Nature       Date:  1997-10-30       Impact factor: 49.962

8.  Measurement of organ blood flow with coloured microspheres in the rat.

Authors:  J P Hakkinen; M W Miller; A H Smith; D R Knight
Journal:  Cardiovasc Res       Date:  1995-01       Impact factor: 10.787

9.  Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase.

Authors:  Y Fukata; K Kimura; N Oshiro; H Saya; Y Matsuura; K Kaibuchi
Journal:  J Cell Biol       Date:  1998-04-20       Impact factor: 10.539

10.  Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association.

Authors:  T Matsui; M Maeda; Y Doi; S Yonemura; M Amano; K Kaibuchi; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1998-02-09       Impact factor: 10.539

View more
  19 in total

1.  Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.

Authors:  Jiqiao Liu; Liping Peng; Juan Yang; Min Wang; Shengnan Xu; Jingmei Liu; Ping Han; Jiayi He; Dean Tian; Qi Zhou
Journal:  Dig Dis Sci       Date:  2015-02-28       Impact factor: 3.199

Review 2.  Statin therapy in patients with cirrhosis.

Authors:  Andrew P Wright; Srinath Adusumalli; Kathleen E Corey
Journal:  Frontline Gastroenterol       Date:  2014-08-08

Review 3.  Stellate cell contraction: role, regulation, and potential therapeutic target.

Authors:  Russell K Soon; Hal F Yee
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

4.  Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.

Authors:  M Hennenberg; J Trebicka; C Stark; A Z Kohistani; J Heller; T Sauerbruch
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

5.  Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.

Authors:  Marike Marjolijn van Beuge; Jai Prakash; Marie Lacombe; Eduard Post; Catharina Reker-Smit; Leonie Beljaars; Klaas Poelstra
Journal:  Pharm Res       Date:  2011-03-26       Impact factor: 4.200

6.  Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.

Authors:  Wei Luo; Ying Meng; Hong-Li Ji; Chun-Qiu Pan; Shan Huang; Chang-Hui Yu; Li-Ming Xiao; Kai Cui; Shu-Yuan Ni; Zhen-Shu Zhang; Xu Li
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

7.  Reactive oxygen species are involved in regulating hypocontractility of mesenteric artery to norepinephrine in cirrhotic rats with portal hypertension.

Authors:  Wei Chen; De-Jun Liu; Yan-Miao Huo; Zhi-Yong Wu; Yong-Wei Sun
Journal:  Int J Biol Sci       Date:  2014-03-15       Impact factor: 6.580

Review 8.  Future therapy of portal hypertension in liver cirrhosis - a guess.

Authors:  Tilman Sauerbruch; Jonel Trebicka
Journal:  F1000Prime Rep       Date:  2014-10-01

9.  Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.

Authors:  Cheng-Gang Zhang; Bin Zhang; Wen-Sheng Deng; Ming Duan; Wei Chen; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

10.  Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.

Authors:  Lai Wei; Juan Yang; Min Wang; Sheng-Nan Xu; Hua-Min Liang; Qi Zhou
Journal:  Int J Mol Med       Date:  2014-08-19       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.